SemBioSys Genetics Inc. recently announced that it has submitted an Investigational New Drug (IND) application for safflower-produced recombinant human insulin to the United States Food and Drug
Administration (FDA). An IND is necessary for a new drug's early preclinical development. "All of our studies to date confirm that our safflower-produced insulin is equivalent to pharmaceutical-grade human insulin. We met our internal schedule to submit the IND and we are on track to begin human clinical trials in the fourth quarter of 2008 as planned," said Andrew Baum, president and chief executive officer of SemBioSys. The company also intends to submit a Clinical Trial Application (CTA) to the appropriate European authorities later this quarter. Assuming approval of the CTA, SemBioSys plans to conduct a Phase I/II trial in the UK.  To read more, visit
http://micro.newswire.ca/release.cgi?rkey=1607298075&view=36078-0&Start=0

Europe's Funding of Worldwide Activism

An Inconvinient Truth (Image):
Nature Biotechnology: Volume 25, Number 12, Dec 2007

EMBO Reports: Contents: Volume 9, Number S1

Bioentrepreneur: From Bench to Boardroom
.....for an update on the latest events focusing on life science entrepreneurship around the world.

How the EU can Fund your Company

Alfalfa Benifits from Medicago truncatula:
 The RCT1 Gene M.truncatula Confers Broad-spectrum Resistance to Anthracnose in Alfalfa

Consortium for Functional Glycomics

Charles's Fantasy Farming Won't Feed Africa's Poor

A Conversation with Nina V. Fedroff , Advocate for Science Diplomacy

Scientists Target Super Cassava

Who Will China Feed?

http://www.businessbhaskar.com/article.php?id=2179 ( Language: Hindi )

Vitamin C and Cancer Revisited

Moving Ahead with an International Human Epigenome Project

Shrewd Survival Strategy ( Tuberculosis )

World Bank Biofuels Report Finally Released :
The combination of higher energy prices and related increases in fertilizer prices and transport costs, and dollar weakness caused food prices to rise by about 35-40 percentage points from January 2002 until June 2008.